METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug hopes to slow liver damage in MASH cirrhosis patients
Disease control Recruiting nowThis study tests an experimental drug called efimosfermin alfa in 42 adults with liver scarring (cirrhosis) from MASH, a fatty liver disease linked to metabolic issues. The goal is to see if the drug is safe and can help control the disease. Participants will receive either the d…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Boston Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 09:02 UTC
-
New drug combo aims to shrink fatty liver in MASH patients
Disease control Recruiting nowThis study tests two experimental drugs, ECC4703 and ECC0509, alone or together, to see if they can reduce liver fat in adults with MASH (a type of fatty liver disease). About 160 participants will receive either the drugs or a placebo for 12 weeks. The main goal is to measure ch…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Eccogene • Aim: Disease control
Last updated May 17, 2026 08:50 UTC
-
New drug aims to shrink fatty liver in early trial
Disease control Recruiting nowThis study tests an experimental drug called ALN-CIDEB in adults with fatty liver disease (MASLD or MASH). The main goal is to check safety and side effects, and also see if it reduces liver fat. About 132 participants will receive either the drug or a placebo.
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New shot aims to halt liver failure in NASH cirrhosis patients
Disease control Recruiting nowThis study tests survodutide, a once-weekly injection, in 1590 adults with NASH or MASH cirrhosis. Participants receive either the drug or a placebo for up to 4.5 years, along with diet and exercise advice. The goal is to see if survodutide prevents serious liver problems like li…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for fatty liver: stomach procedure may beat diet alone
Disease control Recruiting nowThis study tests whether a minimally invasive stomach-shrinking procedure (endoscopic sleeve gastroplasty) combined with lifestyle changes is better than lifestyle changes alone for treating a serious liver condition called MASH in people with obesity. The procedure reduces stoma…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: NA • Sponsor: Pichamol Jirapinyo, MD, MPH • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Healthy volunteers needed to test new fatty liver Drug's absorption
Knowledge-focused Recruiting nowThis early-stage study enrolls 72 healthy adults to see if taking ECC4703 with food changes how the body absorbs it, and to compare four different pill versions. Participants receive a single dose and are monitored for safety and drug levels in the blood. The drug is being develo…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE1 • Sponsor: Eccogene • Aim: Knowledge-focused
Last updated May 17, 2026 08:50 UTC
-
Bariatric surgery study probes hidden cell signals behind fatty liver disease
Knowledge-focused Recruiting nowThis study looks at how tiny communication points inside liver cells (called MAMs) might be linked to a serious liver condition called MASH. Researchers will study 20 adults having weight-loss surgery to see if these cell changes affect disease progression. The goal is to better …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated May 13, 2026 16:02 UTC